Navigation Links
Medivation Reports Third Quarter 2010 Financial Results and Provides Corporate Update
Date:11/5/2010

in Huntington disease and the Phase 3 AFFIRM trial in advanced prostate cancer patients who have failed chemotherapy..

Conference Call InformationTo participate by telephone in today's live call beginning at 4:30 p.m. Eastern Time, please call 877-303-2523 from the U.S. or +1-253-237-1755 internationally.  In addition, the live conference call is being webcast and can be accessed on the "Events and Presentations" page of the "Investor Relations" section of the Company's website at www.medivation.com.  A replay also will be available for 30 days following the live call.

About MedivationMedivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. Together with its corporate partners Pfizer and Astellas, Medivation currently has investigational drugs in Phase 3 development to treat advanced prostate cancer, mild-to-moderate Alzheimer's disease and Huntington disease. For more information, please visit us at www.medivation.com.

This press release contains forward-looking statements, including statements regarding the continued clinical development of Medivation's product candidates, the potential completion of patient enrollment in ongoing clinical trials, the potential initiation of new clinical trials and the potential conduct of an interim analysis in the AFFIRM study, the anticipated timing of announcement of top-line data from ongoing clinical trials and other statements with respect to future clinical trial results, the therapeutic and commercial potential of Medivation's product candidates, the continued effectiveness of, and continuing activities under, Medivation's collaboration agreements with
'/>"/>

SOURCE Medivation, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Medivation Announces Third Quarter 2010 Financial Results Teleconference and Webcast on November 5, 2010
2. Medivation Announces Second Quarter 2010 Financial Results Teleconference and Webcast on August 9, 2010
3. Medivation Announces Organizational Changes to Support Anticipated Growth and Future Commercialization
4. Medivation Reports Third Quarter 2009 Financial Results and Provides Corporate Update
5. Astellas and Medivation Enter Into Worldwide Agreement to Co-Develop and Co-Commercialize MDV3100 for the Treatment of Prostate Cancer
6. Medivation Announces Initiation of Phase 3 Clinical Trial of MDV3100 in Advanced Prostate Cancer
7. Medivation Announces Positive New Efficacy Data From Phase 1-2 Trial of MDV3100 in Advanced Prostate Cancer Patients
8. Pfizer and Medivation Initiate Phase 3 Trial of Dimebon Added to Donepezil in Patients with Alzheimers Disease
9. Medivation Completes Enrollment of Phase 1-2 Trial of MDV3100 in Castration-Resistant Prostate Cancer Patients
10. Medivation Presents Positive New Data on Dimebons Long-Term Efficacy and Novel Mechanism of Action at the International Conference on Alzheimers Disease
11. Medivation Announces Publication in The Lancet of Dimebon Pivotal Trial Results in Alzheimers Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... DIEGO and CARDIFF-BY-THE-SEA, Calif. ... Inc. (NASDAQ: SRNE ;  Sorrento), an ... associated pain, and Conkwest, Inc., a privately-held immuno-oncology ... Natural Killer (NK) cell-line based therapy, announced today ... agreement to jointly develop next generation CAR-TNK™ (pronounced ...
(Date:12/19/2014)... 18, 2014  Decision Resources Group finds that the ... will increase to a value of over ... by expansion in the large direct energy device market. ... increasingly adopted due to the advantages they offer and ... findings from Decision Resources Group,s coverage of the U.S. ...
(Date:12/19/2014)... KANSAS CITY, Kan. , Dec. 18, 2014 ... PETX ), a biopharmaceutical company focused on ... for companion animals, today announced positive results from ... company,s innovative drug for treating pain in dogs ... demonstrated improvements in pain assessment scores that were ...
Breaking Medicine Technology:Sorrento and Conkwest Announce Exclusive Global Collaboration 2Sorrento and Conkwest Announce Exclusive Global Collaboration 3Sorrento and Conkwest Announce Exclusive Global Collaboration 4Sorrento and Conkwest Announce Exclusive Global Collaboration 5U.S. Laparoscopic Device Market Will Reach Over $4.3 Billion by 2023 2U.S. Laparoscopic Device Market Will Reach Over $4.3 Billion by 2023 3Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 2Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 3Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 4Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 5
... University Medical Pharmaceuticals, which specializes in developing and distributing ... to the mass market, announced today that it has ... , Mr. Ten brings 28 years of ... luxury and consumer packaged goods industry. At University ...
... Inc., a company leading the scientific research of neurogenesis ... identify novel pathways for the treatment of central nervous ... Scolnick from the Broad Institute of MIT and Harvard ... to its scientific advisory board. The appointees join BrainCells, ...
Cached Medicine Technology:University Medical Pharmaceuticals Selects Jeffrey Ten as Senior Vice President, International Sales 2University Medical Pharmaceuticals Selects Jeffrey Ten as Senior Vice President, International Sales 3BrainCells Inc. Broadens Scientific Advisory Board Adding Drs. Edward Scolnick and David Holtzman 2BrainCells Inc. Broadens Scientific Advisory Board Adding Drs. Edward Scolnick and David Holtzman 3
(Date:12/21/2014)... The Oncology Institute of Hope and Innovation ... and Whittier offices. The Hope for the Holidays Toy Drive ... and their families during the holiday season. This year, the ... children between both offices. This event continues to be successful ... service team, store managers and assistant managers came out and ...
(Date:12/20/2014)... Weddingshe.com has recently announced its new collection of ... special occasion dresses for the coming new year. ... dresses for global women. Now, all the models on ... 80% off. Among the new items, the model of ... is very popular. What’s more, Weddingshe.com also provides a ...
(Date:12/20/2014)... SATURDAY, Dec. 20, 2014 (HealthDay News) -- The holidays ... when they contend with fresh trees, scented candles and ... and on the decorations that have been packed away ... in my allergy and asthma patients," Dr. Rachna Shah, ... School of Medicine, said in Loyola news release. ...
(Date:12/20/2014)... (PRWEB) December 20, 2014 Atore, Inc, ... company just launched first birthday focused portal on December ... BIRTHDAY MESSAGE” launched in both US and Japan. , ... MESSAGE : http://merrybirthday.net/message/ , MERRY BIRTHDAY MESSAGE ... birthday around the world. , Features, Choose from thousands ...
(Date:12/20/2014)... The Twin Cities DI Day is recognized ... nation! Over 250 financial professionals come together each year ... industry, get motivated to protect their clients and to ... overcoming the challenges of disability. , On September 23rd, ... together to attend The 13th Annual Twin Cities DI ...
Breaking Medicine News(10 mins):Health News:Tons of New-in Winter Sweet 16 Dresses from Weddingshe Online Now 2Health News:Holiday Trimmings Can Trigger Allergies 2Health News:Atore, Inc. Releasing the First Birthday Portal 2Health News:The 13th Annual Twin Cities DI Day Now On Video 2Health News:The 13th Annual Twin Cities DI Day Now On Video 3
... College at Dallas report that contact lenses, both ... materials are expected to reduce the possibility of ... available now. Based in part on these findings, ... hyper-oxygen transmissible contact lenses for 30-day continuous wear.// ...
... way to stop the hair loss associated with drug treatment ... alopecia (CIA), is a frequent side effect of cancer therapy ... time in their lives.// ,Currently, there is no effective ... way doctors can attempt to minimise hair loss is to ...
... have found the genetic mutation that is to blame ... many people.The breakthrough could lead to the development of drugs ... more than one in twelve people suffer from some form ... a history of problems such as panic disorders, agoraphobia and ...
... clues to the high failure rate of cloning and ... core of the nucleus.The discovery, announced at the annual ... Science in Washington, shows that DNA has an internal ... provides clues to how active genes and 'junk DNA' ...
... study, exercise can help older people avert a form ... standing up and walking an impossible one.Those who regularly ... lose abilities to perform activities of daily living. ... Texas, this report is the first to demonstrate that ...
... have developed a screening technique for persons suffering from ... investigations of skin lesions may allow doctors to identify ... particularly those of the colon. ,By looking ... in members of families with a history of HNPCC ...
Cached Medicine News:Health News:New contact lens materials 2Health News:Breakthrough in cancer therapy 2Health News:The anxiety gene, 2Health News:DNA and clones 2Health News:Arthritis risk reduced by exercise 2
... Produces up to 12 L/min of Type ... On Demand, The Super-Q Plus System is ... water which has been pretreated by reverse ... consistently produce ultrapure water quality which exceeds ...
... to 12 L/min of Type I ultrapure ... The Super-Q Plus System is designed to ... has been pretreated by reverse osmosis, distillation ... ultrapure water quality which exceeds Type I ...
... Water for Basic Laboratory Needs, Synergy systems ... flow rate from 1 to 1.2 L/min to ... Synergy 185 system incorporates a dual-wavelength UV lamp ... with low levels of organic contaminants (< 5 ...
... speed, stability and durability. Back-lighted Display. ... multiple units of measure, piece counting ... and GLP/GMP/ISO output including date and ... Built-in, motor-driven internal calibration mass for ...
Medicine Products: